Recently, the 27th World Meeting on Sexual Medicine ( “WMSM” or “the Meeting”) was held in Porto, Portugal. As a highly influential global academic event in the medical field, the congress brought together more than 1,200 experts and scholars from 41 countries, with a total of 940 academic abstracts accepted. The Class 1 innovative drug Tolonadaf Hydrochloride Tablets (brand name: Taituotuo®), independently developed by Yangtze River Pharmaceutical Group ( “YRPG” or “the Group” ), made its debut on the international stage. Its Phase III clinical study abstract stood out from a large number of submissions and was selected as one of the nine “Best Abstracts” at the congress, marking that China’s innovative pharmaceuticals have gained high recognition in the international medical community.
The Meeting featured 32 thematic sessions covering cutting-edge fields including female sexual health, male sexual function, and the development of sexual medicine. Dr. Chengming Gu, Head of the Group’s Marketing Department, was invited to attend the Asia-Pacific Sexual Medicine Forum, where he exchanged insights with global experts on the latest trends in men’s health.
During the academic session, Professor Yuzhuo Yang, an andrology specialist from Peking University First Hospital, delivered a presentation titled: Efficacy and Safety of Tolonadaf, a Novel PDE5 Inhibitor, in the Treatment of Erectile Dysfunction: Key Clinical Evidence. The presentation systematically showcased the clinical development of Taituotuo® in Chinese male patients with ED. Professor Tao Jiang from the Second Affiliated Hospital of Dalian Medical University presented an oral abstract. From a pharmacodynamic perspective, he objectively demonstrated the scientific evidence supporting Taituotuo® in improving erectile dysfunction.
Taituotuo® is a Class 1 innovative drug independently developed by YRPG over more than 20 years of dedicated research and validated by dozens of rigorous clinical studies. In recent years, the Group has continuously strengthened its academic ecosystem in andrology. From participating in the Annual Meeting of the Chinese Association of Andrology and supporting the establishment of the Men’s Health Management Branch of the Chinese Health Management Association, to defining the new concept of shifting from “functional improvement” to “family intimate relationships” in expert advisory meetings, YRPG has gradually built a men’s health service system led by academic research and supported by evidence-based medicine.
During the WMSM, the Group set up a booth in the international exhibition area, highlighting the innovative R&D achievements and pharmacological properties of Taituotuo®. The display attracted many international experts to stop and engage in in-depth exchanges.
This international academic exchange has laid a solid foundation for the Group to further deepen international cooperation and explore global multi-center clinical studies in the future. Building on this milestone, the Group will follow its strategic plan for the “First Year of Internationalization”. It will continue to work closely with experts and scholars from around the world, guided by evidence-based medicine and driven by innovative R&D. The Group will help more domestically developed innovative medicines reach global markets, contributing its part to improving men’s health worldwide and strengthening family well-being.